93.4%
nivolumabsolitomabrelatlimabA375 melanomaNEJM
…he combination strategy of relatlimab (anti-LAG-3 antibody) and nivolumab (anti-PD-1 antibody) approved at the beginning of 2024 as a fir…
14articles mentioning drugs
40drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Relatlimab ×
Relatlimab
This drug is selected. Its supporting articles are shown below.
Articles mentioning Relatlimab
14 articles · page 2 of 2pembrolizumabipilimumabnivolumabrelatlimabUniversity of Wisconsinadvanced stage melanomaunresectable stage III/IV melanoma
…uded: ipilimumab/nivolumab (8/16), nivolumab/relatlimab (7/16), pembrolizumab (1/16). ctDNA change from baseline to 3–4 weeks was not signifi…